Cervomed Inc. (CRVO) — 10-Q Filings

10-Q Filings (6)

• CervoMed's Net Loss Nearly Doubles Amid Soaring R&D Costs — Nov 7, 2025 Risk: high
  CervoMed Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $18,879,077, a 97% increase from the $9,584,781
• CervoMed Slashes R&D, G&A by 90% Amidst Zero Revenue — Aug 8, 2025 Risk: high
  CervoMed Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year, indicating its pre-commercial stage. The com
• CervoMed Inc. Files Q1 2025 10-Q — May 12, 2025 Risk: low
  CervoMed Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Diffusion Pharmaceuticals Inc., is based in Boston, MA, and op
• CervoMed Inc. Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  CervoMed Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Diffusion Pharmaceuticals Inc., is involved in the pharmac
• CervoMed Inc. Files Q2 2024 10-Q — Aug 9, 2024 Risk: medium
  CervoMed Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus M
• CervoMed Inc. Files 10-Q for Q1 2024, Reporting on Financials and Equity — May 14, 2024 Risk: medium
  CervoMed Inc. (CRVO) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. CervoMed Inc. filed a 10-Q for the period ending March 31, 2024. The filing i

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX